ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 19th World Congress on Gastrointestinal Cancer 2017

 

June 28 - July 1 2017 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-LB Efficacy, tolerability and impact on quality of life of ive internal radiation therapy (with yttrium 90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: the SARAH trial Mohamed Bouattour Received Received
  1-P THE LONG-TERM RESULTS OF RADIOFREQUENCY ABLATION (RFA) IN PATIENTS WITH BARRETTS ESOPHAGUS RELATED NEOPLASIA Jana Krajciova Received Received
  1-PD Interference of PG2 TATA BOX region with the serum PG2 level in Gastric Cancer Renato Cannizzaro Received Received
  2-LB A phase Ib/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts) Cindy Oh Received Received
  3-LB Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI /- Bevacizumab (bev) in metastatic colorectal cancer (mCRC) Patients (pts) Marilyn Fontaine Received Received
  5-PD Heterogeneity of MYC amplification in oesophagogastric (OG) carcinoma: results from a prospective screening study Michael Davidson Received Received
  5-P Esophageal cancer patients survival after surgery significantly depended on cell ratio factors, blood cell circuit, biochemical factors, hemostasis system, adjuvant chemoimmunoradiotherapy, cancer characteristics, localization, anthropometric data Oleg Kshivets Received Received
  6-LB Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving ive internal radiation therapy and chemotherapy as first-line therapy Guy Van Hazel Received Received
  6-P Assessment of HER2 status in resected gastric cancer in european population Nieves Martinez Lago Received Received
  7-PD Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3 cecchi Fabiola Received Received
  7-P The metastatic lymph node ratio is an independent prognostic variable in hispanic patients with operable gastric cancer regardless of their TNM stage Eugenia Cordero Received Received
  9-PD Overall survival in patients diagnosed with metastatic GEP-NET in Sweden Daniel Granfeldt Received Received
  9-O Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment Jordi Bruix Received Received
  10-PD A multi-cohort phase 1 study of ramucirumab plus durvalumab: preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma Golan Talia Received Received
  11-O RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC) Filippo Pietrantonio Received Received
  11-P The characteristics of HER2 and c-MET expression in gastric carcinoma and its correlation with clinical-pathological parameters. Florian Dittmar Received Received
  12-P Loss of CDX2 is correlated to high grade and advanced stage in colorectal carcinoma Pathology Deapartement of FSI hospital TUNISIA Haifa Rachdi Received Received
  12-O Impact of prior bevacizumab treatment on VEGFA and PlGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial. Amber Wood Received Received
  13-PD Analysis of risk factors of early recurrence and ideal surgical margin for hepatocellular carcinoma Hidetoshi NItta Received Received
  13-P Symptoms of Gastric Cancer From a Patient Perspective Courtney Eavenson Received Received
  14-O PROGNOSTIC AND PREDICTIVE ROLE OF NEUTROPHILS/LYMPHOCYTES RATIO IN METASTATIC COLORECTAL CANCER: A RETROSPECTIVE ANALISYS OF THE TRIBE STUDY BY GONO. Emanuela DellAquila Received Received
  15-P Epidemiology, treatment and prognostic factors of gastric adenocarcinoma in Tunisia Nesrine Mejri Received Received
  16-O Associations of quality of life with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD Larry Macke Received Received
  16-PD FIRST-LINE THERAPIES FOR ADVANCED PANCREATIC CANCER: A PERSPECTIVE BASED ON PHARMACOLOGICAL COSTS Jacopo Giuliani Received Received
  17-PD CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Sam Wang Received Received
  17-O Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer David Goldstein Received Received
  18-PD Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy Floris de Jong Received Received
  19-P Gastric cancer in young patients: prognostics factors and therapeutic results MARIAM BENHAMI Received Received
  20-PD Right- versus left-side metastatic colorectal cancer: differences in tumor biology and Bevacizumab efficacy. Alessandro Passardi Received Received
  20-O Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma Lipika Goyal Received Received
  23-PD Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated with Immunotherapy Christine Parseghian Received Received
  24-P Metformin Inhibits Growth and Metastasis with Enhancement of Radiation Response in Hepatocellulcar Carcinoma Xenograft Model Won Il Jang Received Received
  24-PD A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results(QUATTRO study) Hideki Furuya Received Received
  25-P Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition Sudhakar Chintharlapalli Received Received
  25-PD Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC):interim analysis from the prospective, observational CORRELATE study Juan Manuel OConnor Received Received
  26-P Coffee and alcohol consumption and liver cancer morbidity rates in Poland Miroslaw Jarosz Received Received
  26-PD Rechallenge with cetuximab irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximabirinotecan: the phase II CRICKET study by GONO. Daniele Rossini Received Received
  27-O Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line ive internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer farah dunlop Received Received
  28-PD Phase II Study of Tivantinib (ARQ 197) and Cetuximab in patients with EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) Lorenza Rimassa Received Received
  29-PD Is Bevacizumab therapy safe in patients with Advanced Colorectal Cancer (CRC) and Self-Expandable Metal Stents(SEMS)? Vilma Pacheco Barcia Received Received
  29-P Collaborative Storage and Research Use of Human Biospecimens between American University of Beirut and Memorial Sloan Kettering Cancer Center WALID FARAJ Received Received
  30-PD Dose finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer: the initial safety analysis Yosuke Kito Received Received
  31-PD Usefulness of 18F-FDG PET/CT, LDH and tumor markers in the prognosis and evaluation of tumor response after RMB therapy in advanced, metastatic colorectal cancer (mCRC) Angelica Nazarian Received Received
  32-PD Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype David Paez Received Received
  32-P Potential Protective Effects of Vitamin E in Cisplatin-induced Toxicity Azadeh Moghaddas Received Received
  34-P Fat consumption and ed gastrointestinal cancers morbidity rates in Poland in the years 1960-2014 Miroslaw Jarosz Received Received
  38-P The role of wnt/ -catenin associated with cell invasiveness in pancreatic cancer Se Jun Park Received Received
  40-P Tanshinone IIA could decrease programmed death-ligand 1 expression in human pancreatic cancer cells in vitro CHIN CHENG SU Received Received
  44-P Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: a single centre experience Rob Owens Received Received
  46-P MORTALITY DURING DEFINITIVE CHEMORADIOTHERAPY IN OESOPHAGEAL CANCER Danielle Shaw Received Received
  53-P Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Andrea Masarykova Received Received
  59-P Radical chemoradiotherapy for patients with locally advanced esophageal cancer. Long-term follow up of an ambispective study. Milana Bergamino Sirvén Received Received
  61-P Role of palliative radiotherapy, chemotherapy and stents for dysphagia and quality of life improvement in advanced esophageal cancer. The optimal management? Aseem Rai Bhatnagar Received Received
  64-P Lymphopenia Association with Planning Target Volume and Lung V5 and its effect on survival of esophageal cancer receiving neoadjuvant chemo-radiation with Dutch CROSS regime Tsz Him So Received Received
  65-P Application of gated FDG PET/CT in target volume definition for radiotherapy in esophageal cancer Pierre Gustin Received Received
  67-P The effect of formalizing perioperative enhanced recovery protocol in esophageal surgery. Maria Yan Received Received
  68-P Controversies in the treatment of esophageal squamous cell carcinoma: transthoracic or transhiatal approach Maria Yan Received Received
  71-P Is Lymph Node Ratio in Surgical Treatment of Esophageal Squamous Cell Carcinoma Better than Classic TNM System? Vítor Devezas Received Received
  72-P Pembrolizumab Versus Investigators Choice Single-AgentChemotherapy in Patients With Advanced/MetastaticEsophageal Adenocarcinoma That Progressed AfterFirst-Line Therapy: Phase 3 KEYNOTE-181 Study Nonnon Kyle Received Received
  76-P Docetaxel in second line in advanced gastric cancer REKAI kheira Received Received
  77-P Predictive factors associated with ramucirumab monotherapy or combination therapy among patients with gastric/gastroesophageal junction cancer in the community oncology setting William Schelman Received Received
  78-P A randomized trial of FOLFIRI versus docetaxel and cisplatin as a second-line chemotherapy after failure of first-line chemotherapy in advanced gastric cancer Sang Kil Lee Received Received
  79-P Discrepancy in Evaluating Her2 Overexpression in Signet Ring Gastric Cancer Deborah Mukherji Received Received
  80-P Evaluation of morphology, HER2 status and its clinical and prognostic correlation in advanced gastric cancer: a prospective study at a tertiary referral center in Lebanon Deborah Mukherji Received Received
  81-P Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States Lisa Hess Received Received
  82-P PROGNOSTIC SIGNIFICANCE OF POSITIVE LYMPH NODE RATIO IN PATIENTS WITH pN3 GASTRIC CANCER WHO UNDERWENT CURATIVE GASTRECTOMY Ahmet Bilici Received Received
  84-P The Detection of RNA for Carcinoembryonic Antigen and Cytokeratin 20 of Peritoneal Washing Fluids in Patients with Advanced Gastric Cancer Se Eun Go Received Received
  87-P Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002) RYOHEI KAWABATA Received Received
  89-P Efficacy and safety of modified Docetaxel, Cisplatine and 5FU (TPFm) in gastric cancer Nesrine Mejri Received Received
  90-P Neoadjuvant chemotherapy in gastric cancer: evaluation of effectiveness Mykola Zubaryev Received Received
  96-P The panitumumab with FOLFOX4 in metastatic Gastric or gastroesophageal Junction Adenocarcinoma (mGA) - VEGA trial. Efficacy and safety outcomes of a phase II S.I.C.O.G. study VINCENZO FORMICA Received Received
  97-P The role of preoperative Computed Tomography for Node staging in Gastric Cancer: a centers retrospective analysis Mário Fontes-Sousa Received Received
  99-P Clinicopathological characteristics in patients with bone Metastasis in GI Cancers Yuki Shimizu Received Received
  100-P TREATMENT OF RECCURENT GASTRIC CANCER Ivans Jelovskis Received Received
  101-P The validity and safety 1st-line Chemotherapy with Capecitabine/Oxaliplatin for Advanced Gastric Cancer Yoshiaki Shindo Received Received
  102-P Intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: A single center retrospective analysis of 71 patients Masahiro Yoshida Received Received
  104-P Real-world gastric cancer patients treated with at least three lines of chemotherapy: outcomes and predictors for efficacy. Valentina Fanotto Received Received
  105-P Modified DOF regimen in advanced stomach cancer A single Centre experience from Bangalore. SATHEESH THUNGAPPA Received Received
  106-P Prognostic factors in metastatic gastric cancer lets take a step forward Amanda Nogueira Received Received
  127-P Evaluation of clinical benefit and safety of anastomotic perfusion measurement in reconstruction of gastrectomy using indocyanine green (ICG) enhanced fluorescence system Mikito Mori Received Received
  129-P Multivisceral resections for T4 gastric cancer Andrii Lukashenko Received Received
  131-P Impact of the number of lymph nodes harvested in gastric cancer patients prognosis Hugo Santos Sousa Received Received
  134-P Safety and Efficacy of Low-dose Decitabine Primed Chemotherapy in Patients with Chemoresistant Relapsed/Refractory Gastrointestinal Cancers Qian Mei Received Received
  135-P The role of serum tumour markers, inflammation-based markers and circulating tumour cells as surrogate biomarkers of early response to neoadjuvant systemic treatment in patients with resectable gastric cancer. Katarzyna Marcisz-Grzanka Received Received
  137-P Analysis of surgical treatment for intrahepatic cholangiocarcinoma Nanako Yasui Received Received
  143-P Prognostic Significance of VEGF and HIF 1 a in Hepatocellular Carcinoma Patients receiving sorafenib versus metformin sorafenib combination Shereen El Shorbagy Received Received
  144-P PECULIARITIES OF POSTOPERATIVE DYNAMICS OF BIOCHEMICAL INDICES OF THE LIVER FUNCTION DEPENDING ON THE CHARACTER OF FOCAL MASSES AND VOLUME OF LIVER RESECTION Saidrakhim Lukmonov Received Received
  145-P Understanding the hepatocellular carcinoma (HCC) patient landscape: Results of the first global survey of people living with HCC Jennifer Gill Received Received
  147-P High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer Kyubo Kim Received Received
  148-P The Role of Quantitative TFPI2 Methylation as A Novel Serum Diagnostic and Prognostic Marker in Hepatopancreaticobiliary Cancers Neslihan Erdem Received Received
  149-P C677T Single Nucleotide Polymorphism of Methylenetetrahydrofolate Reductase Gene and Colorectal Cancer Alshimaa alhanafy Received Received
  153-P Management of anal cancer REKAI kheira Received Received
  154-P Evaluation of risk factors predicting delayed chemotherapy-induced nausea and vomiting in patients receiving low emetic risk chemotherapy (LEC): A prospective, observational, multicenter study Toshinobu Hayashi Received Received
  156-P Endoscopic and oncologic outcomes of gastroduodenal neuroendocrine tumors: A single center, large scale, retrospective study Dong Seok Lee Received Received
  157-P THE PROGNOSTIC FACTORS FOR OPERATED GALLBLADDER CANCER Ahmet Bilici Received Received
  158-P Prospective evaluation of PROMs and acute toxicity in VMAT planned radiotherapy for anal cancer and relation to planning constraints. Camilla Kronborg Received Received
  159-P Epidemiologial study of 414 Gastrointestinal Stromal Tumors (GIST) Mexican patients. German Calderillo Received Received
  160-P Prognosis factors of survival of Gallbladder cancer (GC) in Chile. A retrospective analysis of patients assisted in Hospital Clínico Universidad de Chile. Silvia Catalán Elgueta Received Received
  161-P Can we still improve long term oncologic outcome of patients with anal carcinoma after multimodality treatment? Rodica Anghel Received Received
  164-P FDG PET scanning suggests that 5FU myocardial toxicity is metabolic, rather than ischaemic ANDREW DEAN Received Received
  165-P The Workload and Impact of a Dedicated Cancer of Unknown Primary (CUP) Service on Patients with Imaging Suggestive of Metastatic Disease. Roopinder Gillmore Received Received
  167-P Efficacy and tolerance of XELOX plus Bevacizumab as first line therapy in Moroccan patients with metastatic colorectal cancer Tarik Mahfoud Received Received
  170-P Managing patients with Carcinoma of Unknown Primary: a single UK centre experience Rajarshi Roy Received Received
  172-P Temozolomide and Capecitabine in the treatment of Metastatic Digestive Neuroendocrine Tumor. The experience of a single Portuguese Cancer Centre. Joana Carvalho Received Received
  173-P Bone metastasis from gastrointestinal cancer Taik Mahfoud Received Received
  178-P Frequency Report of Irinotecan Toxicity in Iranian Population: Is genomic differences responsible? Azadeh Moghaddas Received Received
  179-P Non size based morphology criteria for assessment of response in patients with liver metastases of GIT origin receiving systemic treatment Alshimaa alhanafy Received Received
  182-P Stereotactic Body and Conformal Radiation Therapy in Primary and Secondary Liver Malignancies: Local in-field control. Emily Latacz Received Received
  183-P An easy-to-handle DPD deficiency test in saliva to identify patients at high-risk for life-threatening toxicity due to fluoropyrimidine therapy. andres Andrade Galarza Received Received
  184-P Gelatinous Peritoneal Disease (Service Experience). Belkharoubi khedidja Received Received
  185-P Enhanced Recovery After Surgery (ERAS) program in patients undergoing major surgery for gastrointestinal cancer: Results of a 6-year clinical study. Vasileios Alivizatos Received Received
  186-P Clinicopatological analysis of duodenal cancer undergone surgical resection Masaru Inagaki Received Received
  187-P GIST- Retrospective analysis of a district hospital Ins Guerreiro Received Received
  188-P The role of innovative surgical approaches in treatment of gastrointestinal stromal tumors Mark Gluzman Received Received
  191-P Systemic Inflammation Response Index (SIRI): A Prognostic Factor in Pancreatic Cancer (PC) Vilma Pacheco Barcia Received Received
  194-P Evaluation of CA 19-9, a predictive biomarker of response and survival in patients undergoing chemotherapy for metastatic pancreatic ductal adenocarcinoma Doraid Alrifai Received Received
  195-P Second line treatment with 5-Fluorouracil and Folonic acid in Gemcitabine- pretreated advanced pancreatic cancer REKAI kheira Received Received
  199-P Adjuvant therapy for pancreatic cancer: An updated analysis of treatment outcomes in elderly patients using the National Cancer Database (NCDB). Donny Huynh Received Received
  200-P PANOVA-2: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma Updated efficacy results Hugo Siedlecki Received Received
  203-P The relationship between metastatic status and Exosomal Marker (CD63) Expression Using Immunohistochemistry (IHC) in Patients with Pancreatic Ductal Adenocarcinoma (PDAC) Brittany Case Received Received
  206-P Expanded analysis of mFOLFIRINOX as second-line chemotherapy in pancreatic adenocarcinoma ANDREW DEAN Received Received
  207-P Chemoradiation in patients with locally advanced pancreatic adenocarcinoma Oana Trifanescu Received Received
  208-P Resecting the unresectable - long course gemcitabine/nab-paclitaxel followed by chemoirradiation to downstage locally advanced pancreatic adenocarcinoma Andrew Dean Received Received
  210-P The efficacy of single capecitabine as second-line treatment for gemcitabine refractory Pancreatic Cancer Jae kyun Jeong Received Received
  211-P Venous thromboembolic event as prognostic marker in pancreatic and biliary tract cancer Kabsoo Shin Received Received
  212-P Gemcitabine plus Capecitabine in elderly patients with advanced pancreatic cancer. Vasiliki Michalaki Received Received
  214-P Outcomes of Older Versus Younger Patients With Metastatic Pancreatic Cancer: A Single Center Experience Hseyin Engin Received Received
  215-P Progression-Free Survival is a Predictor of Survival in Patients with Untreated Metastatic Pancreatic Cancer: A Systematic Literature Review Melanie Dearing Received Received
  216-P Treatment Patterns and Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Treated With First-Line nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records From the Flatiron Health Database Elizabeth Dawn Flick Received Received
  218-P HCG Experience of Modified FOLFIRINOX regimen in advanced Pancreatic Cancer. SATHEESH THUNGAPPA Received Received
  219-P Gemcitabine and Nab-Paclitaxel based regimen in advanced Pancreatic Carcinoma at tertiary cancer Centre, Bangalore SATHEESH THUNGAPPA Received Received
  220-P Efficacy of oxaliplatin, irinotecan and erlotinib use regarding overall and progression-free survival in gemcitabine-based chemotherapy for locally advanced and metastatic pancreatic cancer. Athanasios Tampakis Received Received
  221-P A simulation-based study on the distribution of TTFields in the body when treating pancreatic cancer Hugo Siedlecki Received Received
  225-P Two hundred Pancreaticoduodenectomies with No Intensive Care Unit Admission at a Single Center in the Middle East: Case for Sub-specialization WALID FARAJ Received Received
  226-P Pancreaticoduodenectomy in the Middle East: A Single Center Experience WALID FARAJ Received Received
  228-P Surgical treatment of pancreatic tumors in children Andrii Lukashenko Received Received
  229-P PanCO: design of an open label, single arm pilot study of OncoSil in subjects with unresectable locally advanced pancreatic adenocarcinoma, given in combination with standard chemotherapy Tom Maher Received Received
  230-P PANOVA-3: A phase 3 study of TTFields with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC) Hugo Siedlecki Received Received
  231-P A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer Vincent Picozzi Received Received
  233-P SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer Somnath Mukherjee Received Received
  234-P Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients Mehrdad Payandeh Received Received
  236-P Proteinase Levels in Colorectal Cancer Pathology and 15 Year Survival LIZ BAKER Received Received
  237-P THE ASSOCIATION OF THE LEVEL SERUM OF INTERLEUKIN-10 AND ITS POLYMORPHISM GENE WITH THE RISK AND THE PROGNOSIS FOR COLORECTAL CANCER IN TUNISIA. jihene ayari Received Received
  239-P Prognostic role of TRAP1 protein network in human metastatic colorectal carcinoma Matteo Landriscina Received Received
  240-P suPAR as an additional prognostic factor in colorectal cancer Ewa Wojcik Received Received
  242-P Correlation between clinical profile and molecular biology in patients from Eastern Algeria with colorectal cancer athamnia houda Received Received
  243-P EMILIN2, extracellular matrix protein, as a regulator of the myeloid response in a model of inflammation-induced colon carcinogenesis. Renato Cannizzaro Received Received
  245-P The survival and KRAS/BRAF testing in colorectal cancer: a review on the literature of Iran Mehrdad Payandeh Received Received
  249-P Outcome analysis of synchronous liver limited vs synchronous lung limited resected metastases from colorectal cancer: a multicenter study Haifa Rachdi Received Received
  250-P Neutrophil extracellular traps promote surgery-induced peritoneal carcinosis of metastatic colorectal cancer via modulation of CXCR2 and av integrin Amr Al-Haidari Received Received
  255-P Autophagy (A) inhibition enhances combined immunotherapy (I) and anti EGFR treatment (E) in colorectal cancer (CRC) Michalis Karamouzis Received Received
  256-P Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade Sarah Novack Received Received
  258-P Factors influencing colorectal cancer screening participation rates in 2016 Isabelle Lawrence Received Received
  259-P EVALUATION OF BRACHYSTEGIA EURYCOMA (HARMS) SEED DIETARY INCLUSION IN THE PREVENTION OF COLON CARCINOGENESIS Sunday Atawodi Received Received
  260-P CHEMOPREVENTIVE EFFECT OF DIETARY PIPER NIGRUM SEED INCLUSION ON N-METHYL-N-NITROSOUREA-INDUCED COLON CARCINOGENESIS IN MALE ALBINO WISTAR RATS Sunday Atawodi Received Received
  261-P EVALUATION OF THE PREVENTIVE EFFECTS OF TELFAIRIA OCCIDENTALLIS LEAF - SUPPLEMENTED DIET ON N-METHYL-N-NITROSOUREA (NMU) INDUCED COLON CARCINOGENESIS IN MALE WISTAR RATS Sunday Atawodi Received Received
  266-P A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer Takeshi Kajiwara Received Received
  267-P Colon cancer: pharmacogenetic approach to personalized conservative treatment Jamshid Ibragimov Received Received
  268-P Lymphocyte-to-monocyte ratio in colorectal cancer patients Zofia Stasik Received Received
  269-P Correlation between the prognostic value of tumor-infiltrating lymphocytes (TILS) and sidedness in colorectal cancer (CC) patients (pts) cristina granetto Received Received
  270-P Prognostic value of molecular biomarkers in mCRC Gonzalo García González Received Received
  271-P Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. Roberto Moretto Received Received
  272-P Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT Fabiola CECCHI Received Received
  273-P Differential clinical outcome according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing of metastatic colorectal cancer patients treated with first line FIr-B/FOx adding bevacizumab to triplet chemotherapy. Gemma Bruera Received Received
  275-P The choice of Irinotecan or Oxaliplatin-based chemotherapy in metastatic colo-rectal cancer as first line treatment: impact on survival (ERCC1 and TOPO1 adjusted analysis) Eugeniu Banu Received Received
  277-P C-Kit and MSI in stage II Colorectal cancer; incidence and prognosis in Egyptian patients. Mohamed Maher Received Received
  278-P Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment Edita Baltruskeviciene Received Received
  280-P The molecular profile of colon cancer cells Panagiotis Parsonidis Received Received
  281-P Expression of folate pathway genes with putative impact on leucovorin metabolism and outcome of patients with advanced colorectal cancer Yvonne Wettergren Received Received
  282-P Pre-treatment Endogenous Interleukin-1 Receptor Antagonist (IL-1Ra) Levels in Metastatic Colorectal Cancer (mCRC) Patients are Associated with Clinical Outcomes After Anti-Interleukin-1a Therapy (MABp1) Ashley Otero Received Received
  284-P Comparison of different sequences of combination chemotherapy and bevacizumab in patients with mKRAS colorectal cancer who received 2 lines of therapy: results of population register of 14 regions of Russia Mikhail Fedyanin Received Received
  285-P Eliminating Fluorouracil Toxicity Without Sacrificing Efficacy In Colorectal Cancer ECE ESIN Received Received
  286-P Evaluation of the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX regimen: a pooled analysis Mototsugu Shimokawa Received Received
  287-P Body mass index and long-term outcomes in stage III colon cancer patients administered postoperative chemotherapy JOLANTA ZOK Received Received
  288-P Prognostic but not predictive: focus on stage II right-sided colorectal cancer tumors Andrea Palloni Received Received
  289-P Association of poor differentiation or positive vertical margin with residual disease in patients with subsequent colectomy after complete macroscopic endoscopic resection of early colorectal cancer Hyun Seok Lee Received Received
  293-P Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gastrointestinal cancers receiving moderately emetogenic chemotherapy regimens Kelly Ostrander Received Received
  295-P Subgroup analysis by progression-free survival (PFS) of Asian patientstreated with regorafenib in the phase 3 CONCUR trial Joachim Kalmus Received Received
  296-P Younger age at presentation of colorectal cancer; just a trend or different biology? Salem Salem Received Received
  297-P Efficacy and toxicity results of FOLFIRI-Aflibercept in advanced colorectal cancer (CRCm) in real life, retrospective study. Prognostic factors and specific populations. López López Carlos Received Received
  298-P Impact of Oxaliplatin on relapse in stage II and III colorectal cancer after primary therapy in Tunisian population Nesrine Mejri Received Received
  299-P Prognostic value of tumor size in stage II and III colorectal cancer in Tunisian population Nesrine Mejri Received Received
  301-P Bevacizumab in the first-line treatment of metastatic right-sided colon cancer: does it influence patients outcome? Veronica Mollica Received Received
  302-P The best overall response to the first-line but not to the second-line treatment correlates with outcome of metastatic right-sided and left-sided colon cancer Giorgio Frega Received Received
  304-P Incidence of oxaliplatin-induced peripheral sensory neuropathy in patients with colorectal cancer treated by FOLFOX regimen at a regional community hospital in Québec. jose luiz guimaraes Received Received
  306-P LLIVE: A Non-interventional Multicenter Study of First-line Avastin (Bevacizumab) in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon Ali Shamseddine Received Received
  307-P Prognostic factors of Survival Outcomes in Colorectal Cancer Patients with Liver Metastasis Pimtip Sanvarinda Received Received
  310-P Primary tumor site (pTS) as a key factor in influencing differential outcome in resected colorectal cancer patients treated with adjuvant XELOX/FOLFOX6 Riccardo Giampieri Received Received
  311-P Regorafenib as third-line treatment for refractory metastatic Colorectal Cancer (mCRC): experience of Hospital de Navarra clinical practice. Elena Mata Velasco Received Received
  312-P Clinical significance of peritoneal CEA detected during operation in patients with colorectal cancer Jae Hyun Kim Received Received
  313-P First report : A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer : HGCSG1503 Satoshi Yuki Received Received
  314-P Randomized Phase II Study of Cetuximab vs. Irinotecan and Cetuximab in Patients with Chemo-refractory KRAS codon G13D Metastatic Colorectal Cancer (G13D-study): Compared with ICECREAM study Keiichiro Ishibashi Received Received
  315-P A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal CancerHGCSG1401 : Analysis of tumor location Satoshi Yuki Received Received
  316-P Prognostic Role of RDW-Platelet Ratio (RPR) in Advanced Colorectal Cancer Hseyin Engin Received Received
  317-P Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cáncer: Safety and efficacy in a real-life population. Beatriz González Received Received
  318-P Properties of the Iranian version of colorectal cancer specific quality of life questionnaire (EORTC QLQ-CR29) Sanambar Sadighi Received Received
  319-P Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer Dawn Batty Received Received
  320-P Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes Batty Dawn Received Received
  321-P Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment Marc Peeters Received Received
  322-P TUMOR LOCATION IN PATIENTS WITH COLORECTAL CANCER TREATED WITH BEVACIZUMAB. Beatriz González Received Received
  324-P MITOMYCIN-C (MTC) AS SALVAGE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC) Jelena Spasic Received Received
  325-P The impact of primary tumor site and anti-VEGF therapy in metastatic colorectal cancer Ana Pissarra Received Received
  326-P Size does matter: comparison of activity between anti-EGFR and anti-VEGF based-treatments in RAS wild type colorectal cancer patients, stratified by sizes of metastatic involvement Michela Del Prete Received Received
  328-P Sidedness and TP53 Mutations Impact OS in anti-EGFR But Not anti-VEGF treated mCRC - An Analysis of the KRAS Registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) Florian Huemer Received Received
  329-P Stereotactic body radiotherapy: a promising approach for colorectal lung oligometastases. Kevin Molina Mata Received Received
  330-P Retreatment with FOLFOX for patients with metastatic colorectal cancer- single center experience Marija Ristic Received Received
  331-P Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals Beatriz González Received Received
  335-P Prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). A 5 year retrospective analysis of our treated population. Gonalo Atalaia Received Received
  338-P RELATIONSHIP BETWEEN PRIMARY TUMOR LOCATION AND ONCOGENES MUTATIONS IN METASTATIC COLORECTAL CANCER. Braulio Martin Calero Received Received
  340-P Increase in Spleen Volume as a Predictor of Oxaliplatin toxicity Ali Shamseddine Received Received
  344-P Clinical Predictive Factors for Surgery in Stage IV MCRC (wt) María Geist Received Received
  345-P Surgical resection of primary tumors in patients with stage IV colorectal cancer and unresectable liver metastases LOURDES CALERA URQUIZU Received Received
  347-P Single-incision versus conventional laparoscopic approach in colorectal cancer surgery LIZ BAKER Received Received
  351-P Simultaneous and staged resections in patients with synchronous colorectal liver metastases Mykola Zubaryev Received Received
  353-P Design of a phase II study evaluating trifluridine/tipiracilbevacizumab and capecitabinebevacizumab for first-line treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy (TASCO1) Sarah Novack Received Received
  355-P The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb) Sarah Novack Received Received
  359-P BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer Sarah Pearce Received Received
  360-P Radical multimodality treatment for locally-recurrent rectal cancer outcomes and potential prognostic factors Thomas Bird Received Received
  362-P Neoadjuvant chemotherapy prior to chemoradiation and surgery for rectal cancer: tolerability, pathological and survival outcomes for a high risk cohort Gary Doherty Received Received
  363-P Longer Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: a monocentric experience. roberto murialdo Received Received
  366-P Prognostic markers of tumour recurrence and survival of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and radical surgery: a retrospective study. Michael Abdalmassih Received Received
  367-P A phase II study of neoadjuvant FOLFOXIRI followed by concurrent capecitabine and radiotherapy for high risk rectal cancer Brigette Ma Received Received
  369-P Treatment in locally advance rectal cancer: Single-center experience. Mariana Rocha Received Received
  372-P Dose escalation utilising a simultaneous integrated boost (SIB) in rectal cancer: outcome of acute toxicity and response Rob Owens Received Received
  374-P Treatment of synchronous rectal and prostate cancer utilising intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB): assessment of acute toxicity and response. Rob Owens Received Received
  378-P Impact of diverting stoma in low anterior resection for rectal cancer on short-term surgical outcomes and reoperation Hussein Fakhry Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
09:00
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 19th World Congress on Gastrointestinal Cancer 2017

 

June 28 - July 1 2017 Barcelona
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 28/06/2017 TO 01/07/2018
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.19wcgic.2017 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 29/06/2017
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster





PosterSessionOnline
Logo Draft
 
Logo Cert